News
3h
Health on MSNRoad to Diagnosis: Patients Share Their MASH JourneysYou might not think much about what makes a liver healthy or unhealthy. And when your liver starts to become unhealthy, you ...
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...
New study finds weight loss jabs not only help tackle obesity but may significantly reduce alcohol use, offering wide health ...
For patients with metabolic dysfunction-associated steatohepatitis and fibrosis, semaglutide is associated with improved liver histologic outcomes.
GLP-1 RA helped resolution of steatohepatitis without worsening fibrosis and reduced liver fibrosis without worsening steatohepatitis.
GLP-1 drug Zepbound leads to greater weight and waist loss than Wegovy in 72-week trial, say researchers at European Congress ...
Findings showed a 13.6% reduction in body weight in the semaglutide 25mg group compared with a 2.2% reduction in the placebo group.
The first head-to-head trial of Mounjaro and Wegovy, the weight-loss drugs, compared the effectiveness of the two leading ...
If you're considering taking a GLP-1 medication, and you also have a digestive condition, you may be wondering about side ...
As the definitive trial comparing Wegovy to Mounjaro is released, experts stress the need for patients to be given the very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results